PARP Inhibitors in the Management of Ovarian Cancer: ASCO …
2020年8月13日 · To provide recommendations on the use of poly (ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search.
For those with germline or somatic pathogenic or likely pathogenic variants in BRCA1 or BRCA2 genes, options should include olaparib (300 mg orally every 12 hours for 2 years), niraparib (200-300 mg orally daily for 3 years) or rucaparib (600 mg twice a day for 2 years).
PARP inhibitors in ovarian cancer: An overview of the practice ... - PubMed
In this review, we provide an overview of the key PARP inhibitor trials that have changed clinical practice, discuss directing therapy according to biomarker status (BRCA and homologous recombination deficiency) and future strategies in ovarian cancer and …
PARP Inhibition in the Ovarian Cancer Patient: Current Approvals …
Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to ...
PARP Inhibitors for Ovarian Cancer: Current Indications, Future ...
2020年4月30日 · PARP inhibitors (PARPIs) have revolutionized the treatment of epithelial ovarian cancer, first for BRCA-associated cancer, and, recently, for all epithelial cancers of serous or high-grade endometr...
PARP Inhibitors as Initial Treatment for Ovarian Cancer
2019年10月29日 · Women with newly diagnosed advanced ovarian cancer may benefit from initial treatment with one of several PARP inhibitors, according to results from three separate clinical trials. The studies tested the PARP inhibitors niraparib (Zejula), olaparib (Lynparza), and veliparib.
PARP Inhibitors in Ovarian Cancer: A Review - PubMed
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for the PARPis olaparib, niraparib, and rucaparib in patients with OC and discusses their role in disease management, w …
PARP inhibitors in ovarian cancer: Mechanisms, resistance, and …
2024年11月1日 · The review article thus focuses on PARPi as a potential drug for ovarian cancer, discussing the mechanisms for PARP (Poly ADP-Ribose Polymerase) in DNA repair, PARPi as a potent treatment strategy in ovarian cancer, and clinical trials governing the use of PARPi for the treatment of ovarian cancer.
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer …
This article offers a short and succinct explanation of the optimal use of PARP inhibitors in high-grade serous ovarian and endometrioid cancer for clinical minds involved in patient care.
PARP inhibitors in ovarian cancer: overcoming resistance with ...
The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance.